Global Health Press

Category - Latest Science

Literature update ViVa week 16-2026

1. MF59-aQIV looks economically persuasive in Korea and Taiwan — but the price assumptions do a lot of the work This modelling study assessed the cost-effectiveness of MF59-adjuvanted quadrivalent influenza vaccine...

ViVa 16 – NEWS around the globe

Global vaccination policy this week feels less like harmonized orchestration and more like controlled fragmentation—with a purpose. European and Western Pacific advisory groups are quietly locking in 2026–2027...

Vaccines and vaccination news

Global WHO and public health WHO’s Technical Advisory Group on COVID-19 Vaccine Composition (TAG‑CO‑VAC) is preparing its next decision on updated COVID‑19 vaccine antigen composition, with a meeting scheduled for May...

Literature update ViVa week 15-2026

1. Long COVID research needs patient peer review – not just patient quotes In a Lancet Infectious Diseases Comment, the authors argue that long COVID research systematically incorporates patient expertise via routine...

Literature update

1. RSV maternal vaccine vs infant immunization (Netherlands) Dutch researchers explored how pregnant women view the two new RSV prevention options for infants: a maternal RSV vaccine in pregnancy and an infant...

Global vaccine production

Global vaccine output remains highly concentrated among a few major producers. Here’s a snapshot of the latest estimates: (Note: Many companies do not publish per‑vaccine production figures; numbers marked with “~” are...

ViVa news – week 13

WHO kicks off World Immunization Week 2026 campaign messaging WHO has rolled out the 2026 World Immunization Week materials under a very on‑brand call to action: “Your decision makes a difference. Immunization for all,”...